Search 

Sygnature Discovery is the UK’s largest independent provider of integrated drug discovery resource and expertise.  Founded in 2004, Sygnature undertakes complete drug discovery programmes and target validation, hit identification, hit-to-lead and lead optimisation projects for pharmaceutical and biotech companies.  Core capabilities include medicinal and synthetic chemistry, in vitro biology/screening, computational chemistry, DMPK and protein crystallography.  Sygnature has an enviable track record of success in delivering multiple clinical candidates.

SYNthesis med chem, founded in 2007, is a relatively new player in the chemistry CRO market. We are Australian owned with laboratory facilities in Shanghai China and offices in Australia, the US and the UK. The management team at SYNthesis are experienced drug discovery professionals with expertise across a range of targets (particularly Kinases, GPCRs and epigenetic targets).

Our clients are drawn from biotech, big pharma and academia, we have an outstanding client return rate with several clients working with us across two or more target classes.